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Side effects (SEs) are the unintended consequence
of therapeutic treatments, but they can also be
seen as valuable readouts of drug effects, resulting
from the perturbation of biological systems by chem-
ical compounds. Unfortunately, biology and chemis-
try are often considered separately, leading to
incomplete models unable to provide a unified view
of SEs. Here, we investigate the molecular bases of
over 1,600 SEs by navigating both chemical and
biological spaces. We identified characteristic
molecular traits for 1,162 SEs, 38% of which can be
explained using solely biological arguments, and
only 6% are exclusively associated with the chemis-
try of the compounds, implying that the drug action is
somewhat unspecific. Overall, we provide mecha-
nistic insights for most SEs and emphasize the
need to blend biology and chemistry to surpass intri-
cate phenomena not captured in the molecular
biology view.
INTRODUCTION
Side effects (SEs) are additional, usually undesirable, conse-
quences of therapeutic treatments. Safety issues may arise at
any developmental stage of a drug and even after its marketing
and testing on the population at large (Giacomini et al., 2007).
Apart from fatal postmarketing consequences, which are rela-
tively rare, unwanted SEs can often lead to harmful or unpleasant
reactions. The current picture in Western countries is that
adverse drug reactions rank closely behind cancer and heart dis-
eases as the major cause of mortality and morbidity (Wu et al.,
2010).
Although unintended, drug SEs constitute a valuable readout
of drug effects in humans, and accordingly, substantial efforts
have been recently invested to catalog the drug-adverse events
scattered in clinical reports (Tatonetti et al., 2012) and drug pack-
age inserts (Kuhn et al., 2010). When appropriately delineated in
databases, SEs may be used as phenotypic profiles that can be
linked with precise molecular data. However, this is not straight-
forward because SEs are the result of complex relationships
emerging from the exposure of a biological system to a chemical594 Chemistry & Biology 20, 594–603, April 18, 2013 ª2013 Elsevierentity and its degradation by-products, in the same way that are
the therapeutic treatments. Unfortunately, biological and chem-
ical entities are often considered separately, which leads to
incomplete models unable to provide a unified view of SEs,
and concerted strategies able to merge and quantify their indi-
vidual contributions to the global behavior of the system are
highly desirable.
The molecular biology view of drug action is that medicines
exert their desired and undesired effects by interacting with
molecular targets. This rationale inspired a systematic analysis
to identify novel drug-target interactions using SE profiles (Cam-
pillos et al., 2008) and has been further reformulated to capture
more complex biological entities, such as pathways (Wallach
et al., 2010) or cellular processes (Lee et al., 2011). From this
perspective, a SE could be seen as a consequence of the mod-
ulation of a known therapeutic target, for instance, because of its
presence in different body tissues. This is the case of morphine,
which achieves analgesic effect by modulating g-opioid recep-
tors in the brain and causes constipation when targeting the
same receptors in the gut (Holzer, 2009). Alternatively, SEs can
be explained by the binding of the drug molecule to nonintended
proteins (i.e., off-targets). For example, Rescriptor, which is an
HIV-1 reverse-transcriptase inhibitor, causes severe rashes by
also interacting with the histamine H4 receptor (Keiser et al.,
2009). However, unfortunately, only a few relationships between
targets and SEs are well documented (Vedani et al., 2012), and
despite remarkable recent progress (Lounkine et al., 2012), the
mechanistic details for most undesired events remain unknown
(Bauer-Mehren et al., 2012).
The traditional pharmacological view of drug action and dis-
covery is somewhat different, as it was based on documenting
the effects of drugs on animal models, rather than exploring
and characterizing all biological mechanisms. Currently, there
is a growing awareness that bioactivity data, and informa-
tion on the behavior of a compound in a biological context,
is mostly encoded within its chemical structure. This assump-
tion has permitted to relate targets showing similar pharmaco-
logical profiles (Garcia-Serna et al., 2010; Keiser et al., 2007;
Mestres et al., 2006) into clusters of seemingly disparate pro-
teins, providing new insights into the function of the targets
(Hillenmeyer et al., 2010).
It is known that some complex or unspecific biological phe-
nomena can be triggered by very well-defined chemical features,
such as the toxicity initiated by electrophilic compounds, formed
either as a drug by-product (e.g., a quinoneimine from paracet-
amol), or as a result of enhanced cellular production of reactiveLtd All rights reserved
Figure 1. A Top-Down Approach into Drug Side Effects
Chemical and biological details of drugs are deployed in order to link detailed
molecular features to phenotypic events.
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such structural alerts were mined in a collection of SEs (Bender
et al., 2007) and used in a follow-up study to build a chemical
map of adverse events that showed a systemic organization
(Scheiber et al., 2009), similar to the pharmacological organiza-
tion that targets show when described from the perspective of
their ligands. However, the general applicability of this strategy
is uncertain, and there are no estimates as to the number, and
types, of chemical moieties that can trigger SEs independently
of their protein targets. Moreover, it is currently unfeasible to
decode structure-activity relationships (SARs) at the organism
level for every drug molecule, because the data are scarce and
they do not explore a significant region of the chemical space.
Some SEs can be understood by analyzing the biology of the
modulated targets, whereas others are better explained by
considering only the chemical properties of the drug compound,
suggesting that no definitive methodology exists to approach
drug SEs departing solely from molecular concepts. Indeed,
the best event predictors are trained mostly from observational
clinical reports that relate drug intakes to SEs (Cami et al.,
2011; Tatonetti et al., 2012), with little attention paid to either
biological or chemical details. Other attempts, alternatively,
included all information available on drugs (Gottlieb et al.,
2011) at the expense of interpretability. Yet, knowledge about
the specific biological or chemical features able to trigger an
adverse reaction is highly desirable as these molecular details
can aid the drug discovery process by informing decisions on
a binding assay choice or a moiety to avoid, for example, and,
at the same time, by building a mechanistic explanation.
Universal solutions are rare in biology, and the faculty to
explain a phenotypic event with a few molecular concepts is
often a matter of choosing the right focus. Accordingly, we
analyze here a comprehensive collection of drug SEs, and for
each of them, we assess whether a biological or a chemical
perspective, or a combination of both, is the most adequate to
reveal its molecular bases. That is, we rationally blend two dispa-
rate perspectives to quantify their contribution to SEs, which
should ultimately lead to a unified view of drug effects in humans.
RESULTS AND DISCUSSION
Our analysis consisted in a top-down approach, where drugs
were classified at the phenotypic level, and associations with
molecular characteristics were agnostically proposed therefrom.
We gathered and organized molecular details for each com-
pound in a way that represents the current biological and
chemical mindsets (Figure 1).
The first layer of biological details included the intended
targets of a drug molecule. Then we complemented therapeutic
targets with proteins linked to the drug molecule in a chemical-
protein interactome, in order to include possible off-target
effects. Additionally, we considered the possibility that the
modulation of distinct proteins participating in the same cellular
process, or devoted to a particular function, might have similar
phenotypic implications (Lee et al., 2011; Wallach et al., 2010).
With these levels of biological organization, we expect to gain
power in detecting simple biological descriptions that are related
to SEs, although not necessarily through the interaction with the
same proteins.Chemistry & Biology 20,Regarding the chemical perspective, we used in the first place
small 2D fragments, which have proven useful to build interpret-
able SARs (Pauwels et al., 2011) and have the virtue of being
recognizable by the organic and the medicinal chemist, despite
not including properties like rigidity or lipophilicity (Oprea and
Gottfries, 2001). Similarly, we built a network of molecular scaf-
folds (Varin et al., 2011) following Murcko’s rules (Bemis and
Murcko, 1996). These rules imply a recursive pruning of mole-
cules and have been proposed to guide the navigation of chem-
ical libraries in amanner that is biologically relevant (Wetzel et al.,
2009). Finally, we also explored an organic chemistry vocabulary
that organizes the structural features of compounds (de Matos
et al., 2010).
Summary of the Methodology
Aschemaof themethodological strategy is presented in Figure 2.
To identify overrepresented biological or chemical features that
might be indicative of a given effect, we analyzed a collection
of 1,626 clinical events extracted from 992 drug package inserts
(Kuhn et al., 2010). We then classified the drugs into different
SEs, where a single drug might occur in multiple SEs depending
on the number of reported events, and we tested the overrepre-
sentation of molecular features among drugs using appropriate
statistical approaches (see the Experimental Procedures). The
outcome of the enrichment analysis is, for each SE, a collection
of different overrepresented traits, which could potentially play a
role in the development of the SE. Our top-down approach gen-
erates simple associations at different depths of biological and
chemical details (from therapeutic targets to pathways, and
from small fragments to large scaffolds), thus favoring individual,
well-defined, and testable findings (Figure 1).
Finally, we used the enriched molecular features to propose
simple drug classifiers, which now allow for features to be
combined, and evaluated their performance by means of the
F1-score (Equation 1), a common measure to balance precision
and recall. Here, precision is calculated as the number of drugs
correctly identified as causing a given SE (i.e., true positives)
over the total number of drugs predicted to cause it (i.e., true
positives + false positives), and the recall is given as fraction of
true positives over the total number of drugs causing the SE594–603, April 18, 2013 ª2013 Elsevier Ltd All rights reserved 595
Figure 2. Scheme of the Methodology
(A) Drugs that cause each of the SEs are collected, and the biological and chemical profiles of these drugs are extracted from several resources.
(B) An enrichment analysis is performed for each SE feature pair, based on contingency tables counted on the number of drugs that cause the event and the
number of drugs related to the feature.
(C) After a multiple testing correction, an overrepresentation profile is proposed for the different types of features.
(D) A cross-validated classification exercise helps to address the comprehensiveness of the overrepresentation profile and the possible advantages of combining
observations of different types.
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these classifiers should not be considered as the endpoint of our
analysis. As explained above, for an exhaustive collection of
SEs, we perform a search for individual molecular traits that
appear strongly associated to the events. In this context, an
F1-score measures if such molecular details are specific to the
drugs that cause the event (precision) and account for most of
the drugs (recall). Therefore, high F1-scores correspond to those
SEs for which our findings are sufficient to identify many of the
related drugs, with strong certainty that safe compounds (i.e.,
those not causing the SE) do not share the proposed molecular
profiles. On the contrary, low F1-scores correspond to cases for
which our findings only belong to a fraction of the SE-causing
drugs, possibly without a specific and complete description
because safe drugs exist with the traits associated with the
event. Note that scarce drug safety records, and the fact that
drug target profiles are not complete (Mestres et al., 2008),
contribute to low F1-scores. Thus, overall, we argue that classi-
fication performance can be seen as a measure of comprehen-
siveness of our molecular discoveries, i.e., the proportion of
drugs to which molecular models are applicable and the cer-
tainty that drugs fulfilling the molecular requirement will cause
the given SEs. Accordingly, F1 is used to prioritize our SEmodels
in this global analysis but should not be taken as an assessment
of the true association between individual molecular traits and
SEs, which we controlled in the statistical analysis. For discus-596 Chemistry & Biology 20, 594–603, April 18, 2013 ª2013 Elseviersion in this paper, we considered that combinations of biological
and/or chemical features with F1-scores > 0.5 provide descrip-
tions that are fairly comprehensive.
Flagging Biological and Chemical Details
Figures 3 and 4A illustrate the features most commonly associ-
ated to SEs and three representative portions of the molecular
models built around each SE, respectively. The complete results
are provided in Tables S1 and S2 (available online). Concretely,
for each SE, we indicate which biological and/or chemical fea-
tures are overrepresented and assess their use to build classi-
fiers with the F1-score. We also propose an optimal classifier
that may benefit from the integration of different feature types,
specifying its precision and recall.
We could find overrepresented biological or chemical features
in 1,162 (71%) SEs; all statistics hereafter refer to this subset of
events. Out of these 1,162 SEs, we obtained a model with an
F1-score > 0.5 for 164 (14%) by using enriched features as
parameters. These are cases for which we have identified com-
binations of biological and/or chemical traits whose occurrence
is almost invariably associated to a SE (average precision of 0.74
within the [0.49–1] range) and that are present in most drugs
known to cause this effect (average recall of 0.59 within the
[0.36–1] range). On the other hand, in 432 (37%) of the SEs,
our features were not sufficient to alert the event for any of the
drugs in a cross-validation. In between, almost half of the SEsLtd All rights reserved
Figure 3. Features Most Commonly Associated to SEs
Each row represents a feature type, and features are ranked by decreasing number of associated SEs; only the top ten features are shown. For each feature, the
size of the bubble is proportional to the number of associated SEs, and the opacity corresponds to the frequency of the feature among drugs in the data set. Some
of the bubbles refer to more than one feature; in such cases, the properties of the bubble are those of the top-ranking feature, and the remaining features are
specified within parentheses. A detailed description of all of the traits associated to SEs is provided in Table S2.
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hensive (0 < F1 % 0.5), with an average precision and recall of
0.62 and 0.21, respectively.
Abundant, yet Insufficient, Biological Knowledge
We associated biological features to a majority (94%) of SEs.
As expected, for most SEs we captured entities of different
types (biological processes, pathways, proteins, etc.) because
all these types refer to the same initial drug-protein interactome
(Figure 4C). To assess these findings, we first checked whether
our systematic approach was able to flag proteins that are
commonly alerted by toxicologists, related to endocrine and
metabolic disruption, cardiogenicity, and cardiotoxicity (Vedani
et al., 2012). Thirteen out of the 16 proteins associated to
these adverse events were present in our drug-protein interac-
tion data. We found 10 of them overrepresented in at least
one SE, and remarkably, 9 were enriched in a number of
SEs above the median (Table S4). In addition, we conducted a
bibliometric study to assess how many of the known associa-
tions we are able to recapitulate as well as how many have
not been reported before. Our analyses suggest that the
majority of the relationships identified may be novel, with the
estimation that our biological explanation had already beenChemistry & Biology 20,reported for only 16% of the SEs (Table S3; Supplemental
Experimental Procedures).
Interestingly, in 674 (58%) of the cases, the adverse and the
therapeutic mechanisms correlated. For example, all of the 10
drugs intended to target the angiotensin-converting enzyme
(ACE) cause pulmonary eosinophilia (Figure 4B), which agrees
well with what is known about ACE inhibitors, their mechanism
of action, and possible off-target effects (Trifilieff et al., 1993;
Vasquez-Pinto et al., 2010).
A potential pitfall when considering only intended therapeutic
targets is that we can erroneously infer noncausal associations
between these and SEs, when the actual effectors are off-targets
shared by molecules of the same therapeutic class. However,
the real causal relationships should emerge if we include off-
target proteins in the analyses. In doing so, we proposed liable
proteins in 77% of the SEs. On average, six proteins were
overrepresented per SE (Table 1). In principle, these findings
include causal drug-protein interactions and can thus hint
mechanistic insights. For instance, our analyses show that four
out of the seven drugs that cause respiratory paralysis interact
with the KCNQ1 and SCN10A voltage-gated channels, thereby
interfering with the neuromuscular apparatus (Figure 4B), in594–603, April 18, 2013 ª2013 Elsevier Ltd All rights reserved 597
Figure 4. Overrepresented Features to Explain Drug SEs
(A) This panel shows three representative portions of the results SE-wise (see also Table S1). Filled cells in the main matrix refer to SEs for which we detected
enrichment signals. Cells in the main matrix are color-graded according to the F1-score. Columns on the right refer to the optimal classifiers, built by combining
the spotted molecular views. In addition, a normalized measure of the information gain upon classification is given in gray-scale. The bar plot on the right
represents the number of drugs that were reported to cause each SE. Finally, the bar plot on the top adds up the SEs with overrepresented features. The
proportion of these that led to classifiers and contributed to an optimal model is progressively dark shaded.
(B) Illustrative examples linking adverse events to detailed molecular features.
(C) The underlying biology and chemistry of SEs. Venn diagrams join SE sets for which enrichment signals were found. For simplicity, the ‘‘proteins’’ circle groups
the ‘‘therapeutic targets’’ and the ‘‘protein interactors’’ categories, and ‘‘processes and functions’’ joins ‘‘biological processes’’ and ‘‘molecular functions’’.
See also Figures S1 and S2.
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The other three drugs, namely, dextrose, magnesium ion, and
pyridostignin, are pharmacologically distant, but they are all
reported to bind the coagulation factor X. How this translates
into respiratory paralysis is more difficult to comment on, as to
the best of our knowledge, mechanistic links between factor X
and respiratory paralysis has not been established.
Beyond rationalizing and quantifying known associations
between drug targets and SEs, our method is able to hypothe-
size relationships. An effective strategy to extract compelling
mechanistic insights among these putative SE-protein associa-
tions is to look for overrepresented proteins that interact with
disease-related genes (see the Supplemental Experimental
Procedures for further details). For example, 35 drugs in our
data set may induce ileus paralytic, which refers to intestinal
pseudo-obstruction due to severe abnormality of gastrointes-
tinal motility. Dopamine receptors (DRs) D2 and D3 are overrep-
resented as targets among these 35 drugs and have not been
previously related to this SE. Also, drugs that target DRD2 and/598 Chemistry & Biology 20, 594–603, April 18, 2013 ª2013 Elsevieror DRD3 do not interact with any of the ileus-related gene
products (Davis et al., 2013), meaning that no alternative and
trivial mechanism of action can be proposed. Interestingly,
DRD2 and DRD3 physically interact with filamin A (FLNA); dupli-
cation of FLNA gene has been associated with intestinal pseudo-
obstruction phenotypes (Clayton-Smith et al., 2009). Also, FLNA
is known to play an important and selective role in the localization
of DRD2/3 (Lin et al., 2001). Thus, we hypothesize that blockade
of DRD2 and/or DRD3 may result in aberrant behavior of this
mechanism, possibly acting on the same molecular processes
that are altered upon the disease-related duplication of the
FLNA gene.
Another interesting example regards the pathologic deposi-
tion of calcium salts in tissues, termed calcinosis. We found
that three of the seven drugs that cause calcinosis interact
with matrix metallopeptidase 1 (MMP1). This enzyme shows a
certain specificity to cleave the monocyte chomoattractant pro-
tein 2 (MCP2) (McQuibban et al., 2002), and the integrity of the
MMP1 catalytic domain has been proposed to be required forLtd All rights reserved
Table 1. Summary of Results
SEs SE-Features
Distinct
Features F1 > 0.5
Therapeutic targets 674 1,457 79 24
Protein interactors 905 5,466 323 40
Pathways 631 4,281 154 31
Biological processes 727 9,727 835 38
Molecular functions 705 5,766 310 43
Small fragments 564 6,630 452 44
Scaffolds 429 586 74 19
Structural terms 427 694 105 26
Biology 1,904 2.7 3 104 1,701 73
Chemistry 716 7.9 3 103 631 59
‘‘SEs’’ refers to the number of SEs for which enriched features were
found. ‘‘SE-Features’’ is the total number of SE-feature relationships;
‘‘Distinct Features’’ counts the unique features that were overrepre-
sented in at least one SE. Finally, ‘‘F1 > 0.5’’ refers to the number of
comprehensive models.
See also Tables S3 and S4.
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metallopreoteinases-1 (TIMP1) (Vallon et al., 1997). Drugs that
interact with MMP1 can thus interfere with its ability to engage
MCP2 and TIMP1. Interestingly, these two genes were detected
in a recent study to rationalize therapeutic effects in aortic valve
calcification (Shuvy et al., 2011), strongly suggesting that drug
interference with MMP1 could trigger calcinosis.
Whereas some SEs can be rationalized as shown in the pre-
vious examples, others are more related to drug metabolism
issues. In this regard, it is worth noting that cytochromes P450
were recurrently overrepresented, e.g., CYP3A4 was associated
with 214 SEs (Figure 3). This observation is in good agreement
with the recent estimate that targets of drug metabolites may
be involved in up to 40% of the adverse events (Bauer-Mehren
et al., 2012). We decided not to include drug metabolites in our
analysis, because drug by-products are only identified upon
administration in body systems or predicted, most notably, by
means of cytochrome catabolism experiments (Fura, 2006).
Our approach illustrates the tendency to overlook the identity
of metabolites at the drug discovery stage (Fura, 2006). In line
with this, and aware of the lack of completeness in drug-protein
interaction data (Mestres et al., 2008), we propose that our bio-
logical insights may be read as a quantification of the usefulness
of our current knowledge on the molecular biology of medicines
to explain their adverse events.
Remarkably, we could only propose a model with F1 > 0.5 for
73 (6%) SEs, even when we had 2.7 3 104 SE associations with
proteins, pathways, biological processes, and molecular func-
tions (Table 1). This means that, although there is already abun-
dant biological information, it is not yet enough to explain the
complexity of effects observed in clinical trials. Moreover, the
predictive power of proteins was similar to that of pathways, bio-
logical processes, or molecular functions, suggesting that, in the
majority of cases, these annotations alone are not enough to
scale-up to a phenotype. In order to gain predictive power, our
identification of potentially harmful proteins should be integrated
with other types of biological data (i.e., presence of paralogs thatChemistry & Biology 20,can compensate for each other’s function, backup circuits,
expression in different tissues) into systems biology models
able to weight their contribution and establish the functional
causes of SEs. For this purpose, our findings, which constitute
individual biological alerts, can be particularly useful as seeds
in the elaboration of complex network biology models (Soler-
Lo´pez et al., 2011).
Predictive, yet Limited, Chemical Details
We detected chemical traits for 716 (61%) SEs. On average, we
spotted 11.8 small fragments, 1.4 scaffolds, and 1.6 structural
terms for each SE. The several small fragments related to each
SE may be used in SAR models, whereas the more informative
scaffolds and structural terms may be proposed as liable fea-
tures to avoid when designing safer drugs. It should be noted
that molecules in this study correspond to optimized chemo-
types, and thus our findings are enriched with structural alerts
that might not be currently known to have SEs. Interestingly,
19% of the associated small fragments could be found among
disease-related environmental chemicals (Table S4).
Overall, we collected 7.93 103 associations between SEs and
chemical traits, three times less than in the case of biological fea-
tures. Still, we could generate 59 comprehensive classifiers
solely based on chemical details (Table S1). Of these, 27 lacked
a plausible biological model, suggesting that the chemistry of the
compounds alone may be responsible for the SEs. Overall, we
observe that, although the number of chemical features associ-
ated to a SE is scarcer than biological traits, their predictive
power is on average superior. An example is xanthopsia, which
refers to the predominance of yellow in vision. In drugs causing
it, we observed an overrepresentation of the small fragments
depicted in Figure 4B. The biological mechanism underlying
xanthopsia is not yet clear, despite the interest aroused by
the suspicion that this condition influenced Vincent van Gogh’s
‘‘yellow period’’ (Arnold and Loftus, 1991). Nonetheless, the
small fragments we flagged, combined to form e.g., thiazides
or sulfonamides, recalled with full precision 7 out of the 13
drugs that cause this SE. Similarly, by considering only the
cephalosporin and the tetracycline scaffolds, we predicted
nephropathotoxicity with 47% recall and 85% precision. Several
antibiotics are mounted on these two scaffolds long known to be
toxic in the kidney. In fact, the first attempts to elucidate the
mechanism of cephalosporin toxicity were purely chemocentric
(Tune and Fravert, 1980); we recovered this knowledge in an un-
biased systematic fashion.
One can suspect that, if no biological signal is found, then the
drug action is somewhat unspecific. We found that as low as 6%
of the 1,162 SEs can exclusively be associated with chemistry
(Figure 4C), implying that only a small proportion of SEs appear
unrelated to drug targets. However, this may well be an underes-
timate given the abundance of overtargeted cytochromes in
our findings: drug-metabolizing enzymes can certainly produce
reactive by-products, thereby leading to nonspecific alterations.
Chemistry to Complement Biology
For 648 (56%) SEs, we detected both biological and chemical
features. In some cases, the two views seemed complementary.
For instance, uncontrolled movement of the body, termed
buccoglossal syndrome, is caused by six drugs in our data set.
Buccoglossal syndrome is a common event among antipsy-
chotics (Blanchet et al., 2012). Accordingly, we found an594–603, April 18, 2013 ª2013 Elsevier Ltd All rights reserved 599
Figure 5. Systemic Clustering of Biological and Chemical Details
(A and B) Filled cells correspond to SOCs annotated to SEs with overrepresented features. The clustering of SEs within each SOC is given a significance P-value.
As illustrative examples, we highlight chemical scaffolds related to blood and lymphatic disorders (A) and proteins associated to vascular disorders (B).
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amine receptor 5-HT2A and the dopamine receptor DRD2. Also,
we found that a significant proportion of the molecules that
cause this SE contain the privileged piperazine moiety (Fig-
ure 4B). There are 44 molecules that target 5-HT2A and/or
DRD2, and 33 of those contain the piperazine ring, but only 6
of them are known to cause the syndrome. Hence, models built
with these features separately failed to correctly identify such
drugs. However, by screening for 5-HT2A and/or DRD2 modula-
tors that contain a piperazine ring, we could classify drugs with
80% precision and 67% recall. For other SEs, we observed
redundant signals: 25 out of the 31 drugs that cause skin striae
contain the steroidal scaffold depicted in Figure 4B. In parallel,
we also found skin striae related to glucocorticoid signaling,
which is mediated by steroidal hormones. Here, both the chem-
ical and the biological views refer to the modulation of hormonal
receptors in the skin, well known to be involved in striae forma-
tion (Blanchet et al., 2012).
Overall, 57% of the comprehensive classifiers were obtained
by mixing biological and chemical details. Accordingly, we pro-
pose that chemical information, usually ciphered and limited,
could be used to account for unspecific or intricate phenomena
unperceived by classifiers based on the molecular biology of
drugs.
A Systemic Organization
We finally assessed to what extent the identified feature-SE rela-
tionships are common within SEs occurring in the same system
or organ class (SOC), since this could be a good indicator to
guide toxicological tests without the need for full body systems.
With this aim, we used all of the SE-feature associations (Table
S2) and calculated the overlap of enriched features among the600 Chemistry & Biology 20, 594–603, April 18, 2013 ª2013 ElsevierSEs annotated to each SOC, as defined in theMedDRA terminol-
ogy (http://medrramsso.com). As shown in Figure 5, psychiatric
disorders, for instance, map to characteristic regions both on the
chemical and the biological spaces. On the other hand, for meta-
bolism and nutritional disorders our findings are sparse, sug-
gesting that a diverse spectrum of drug-protein interactions
and chemical moieties may elicit them. Interestingly, issues in
the blood and lymphatic systems are poorly organized by the
biological view but are related to a well-defined chemistry (Fig-
ure 5A), in good agreement with the isolated chemical cluster
found in Scheiber et al. (2009). Conversely, therewas a collection
of targets that mostly correlated with vascular disorders. In Fig-
ure 5B, we zoom into a cluster of vascular events related to
adrenergic receptors (ADRB1/2/3), the renin-angiotensin system
(REN and ACE) and drug metabolism (CYP2D6 and SLC15A1/2).
This protein-centered view is compatible with the recent claim
that molecular biology can model satisfactorily cardiovascular
complications (Berger and Iyengar, 2011).
SIGNIFICANCE
We have performed an exhaustive search for chemical
and biological molecular traits in a diverse collection of
human phenotypic responses to drug treatments. Taking
an agnostic approach, we have been able to recover knowl-
edge accumulated over the years and, most importantly,
suggest molecular mechanisms mediating drug SEs that
are poorly understood. However, although we discovered
biological traits related to most SEs, we were only able to
suggest a comprehensive model for a relatively small pro-
portion of them. Notably, our results also highlight that,
for half of the SEs with underlying biological causes, theLtd All rights reserved
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late. On the other hand, a chemocentric approach seemed
more assertive, even though chemical features were
harder to flag. We found that roughly 6% of the SEs are
exclusively associated to the chemistry of the compounds,
perhaps implying that the drug action is unspecific. As
expected, our analyses emphasize the need to blend
biology and chemistry to provide molecular explanations
of complex SEs.
Overall, we provide sets of detailed biological and chemi-
cal features that are strongly overrepresented among the
compounds causing a given event. We have presented
some illustrative examples, but, to get the most out of our
analysis, the overrepresented features detailed in Table S2
should be considered along the drug discovery process.
Additionally, our findings confirm that reductionist ap-
proaches are often insufficient to anticipate drug SEs
(Berger and Iyengar, 2011), where genetic variability is
known to play an important role (Becquemont, 2009; Gurwitz
and Motulsky, 2007). We anticipate that, for a significant
number of events, the emerging field of systems biology
will help to understand how complex signals propagate
through cellular networks, eventually unmasking silent
phenotypes.
EXPERIMENTAL PROCEDURES
The experimental pipeline is schemed in Figure 2. First, data is collected. Then
enrichment analyses are performed exhaustively for all of the SEs and for each
of the molecular features. The overrepresentation profile for each of the SEs
constitutes the bulk of our results. Finally, we perform a prediction step to
assess the comprehensiveness of our findings.
Data Sets
Drug Side Effects
We collected information on drugs and their SEs from SidER (v. 2) (Kuhn et al.,
2010), a resource of compiled drug package inserts that uses the MedDRA
dictionary, which is accepted as a standard, clinically validated terminology
for SE reporting. SEs were fetched at the ‘‘preferred term’’ (PT) level and
labeled with the corresponding ‘‘system organ classes’’ (SOCs) fromMedDRA
(v. 14.1). We discarded SEs caused by less than 5 drugs to ensure statistical
robustness, obtaining a space of clinical events composed of a set D of 992
drugs related to a set S of 1,626 MedDRA PTs. Drug SEs were considered
regardless of their frequency.
Biological Space
Therapeutic Targets
The DrugBank database (Knox et al., 2011) combines detailed drug data with
comprehensive drug target information, providing a rich picture of the current
knowledge on the pharmacology of drugs. Accordingly, the human targets
with known pharmacological action in DrugBank constitute a plausible anno-
tation of therapeutic targets. Drugs were mapped to the DrugBank database
(v. 3) using their PubChem (http://pubchem.ncbi.nlm.nih.gov) compound iden-
tifiers. The mapping was further covered using name and structure matching.
We achieved the latter by encoding InChIKeys after stripping salts, removing
hydrogen atoms, and merging stereochemistry with OpenBabel (v. 2.3.1)
(O’Boyle et al., 2011). Overall, we fetched 88 human proteins targeted by at
least 5 drugs in D; this same criterion was used for the rest of the feature types
below.
Protein Interactors
The STITCH database (Kuhn et al., 2012) is an aggregate repository that cap-
tures as much as possible of the publicly available knowledge on protein-
chemical interactions. Wematched the compounds inD to the flat compounds
in STITCH (v. 3) and retrieved their human protein interactors. We required aChemistry & Biology 20,confidence score higher than 0.7 supported by either databases or experi-
ments. In total, we collected 702 gene products from STITCH.
Pathways
To link drugs and human pathways, we mapped STITCH proteins to KEGG
(Kanehisa and Goto, 2000) using the KEGG.db Bioconductor package
(v. 2.9) (Gentleman et al., 2004). 203 pathways entered the analysis.
Biological Processes and Molecular Functions
The full gene ontology (GO) was downloaded (data v. 1.1.2491) and separated
into three directed acyclic graphs (DAGs), namely, ‘‘biological process’’,
‘‘molecular function’’, and ‘‘cellular component’’, considering only ‘‘is a’’ rela-
tionships. We annotated STITCH proteins to the leaves of the ‘‘biological
process’’ and ‘‘molecular function’’ subontologies using the Ensembl cross-
references of the biomaRt Bioconductor package (Gentleman et al., 2004).
The subgraphs spanning all of the protein annotations from the leaves to the
roots had a size of 6,353 and 2,123 nodes, respectively.
Chemical Space
Small Fragments
PubChem provides 2D structural descriptions of molecules through CACTVS
fingerprints. CACTVS fingerprints denote the presence or absence of 881
structural features. Although not strictly limited to small fragments, CACTVS
representations embrace a wide spectrum of structural concepts, such as
element counts, types of ring systems, or atom pairings. In total, we con-
sidered 552 CACTVS fragments.
Scaffolds
A scaffold network was generated as described in Varin et al. (2011). A scaf-
fold network of chemicals consists of molecular scaffolds and smaller parent
scaffolds generated by the pruning of rings (Bemis and Murcko, 1996), effec-
tively leading to a map of substructure relationships. The resulting network
from PubChem structures of D formed a DAG of 197 nodes, with minimal
scaffolds as roots and the molecules without terminal side chains as leaves.
Structural Terms
ChEBI (de Matos et al., 2010) is a dictionary of molecular entities that includes
groups and classes of structures (e.g., imatinib is annotated in ChEBI with
‘‘diazine’’ and ‘‘piperazine’’ terms). The ChEBI ontology (data v. 90) was down-
loaded and converted to a DAG by removing cyclic relationships (‘‘is tautomer
of’’, ‘‘is enantiomer of’’, etc.) and merging the others into a single ‘‘is a’’-like
relationship (Ferreira and Couto, 2010). The strategy to map D onto ChEBI
was analogous to that onto DrugBank.We spanned the ‘‘chemical entity’’ sub-
graph as it was done for the GO terms, obtaining a network of 467 nodes.
Analyses
Feature Enrichments
For each SE, we aimed at profiles of overrepresentedmolecular features of the
eight types above (‘‘therapeutic targets’’, ‘‘small fragments’’, etc.). We per-
formed multiple univariate right-tailed Fisher’s exact tests in each feature
type. Univariate Fisher’s test were calculated under the null hypothesis that
drugs that cause the SE are not more likely to contain the molecular feature
of interest. Only features belonging to at least one of the SE-related drugs
were tested, and we applied a Bonferroni multiple testing correction to keep
the family-wise error rate below 0.05.
In the case of features with an inherent tree-like structure (i.e., GO terms,
scaffolds, and ChEBI structural terms), the ‘‘Elim’’ method was implemented
to investigate from the most specific features to the most general ones (Alexa
et al., 2006). Briefly, the algorithm starts processing the nodes from the leaves
and iteratively travels to parental nodes. Because nodes from the same level
share no edge, they can be investigated independently, and the Fisher’s tests
above may be performed. When a node is processed, the drugs responsible
for a significant enrichment signal in a previous step are removed from the
test, thus prioritizing specific overrepresentations and decorrelating the DAG
structure to provide distinct findings.
Performance of Findings as Classifiers
The discriminative potential of overrepresented features was examined by
using decision tree classifiers based on Gini’s impurity as implemented in
the Scikit-learn Python package (Pedregosa et al., 2011). We evaluated the
accuracy of the classification by means of the F1-score after a leave-one-
out (LOO) cross-validation, which respects sample proportions (see the
Supplemental Experimental Procedures for further information). In a LOO594–603, April 18, 2013 ª2013 Elsevier Ltd All rights reserved 601
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used to derive the prediction for such left-out compound. After a prediction is
derived for all of the drugs, the precision can be calculated as the number of
true positives over the total number of positive predictions, whereas the recall
scales the true positives over the total number of drugs known to cause the SE
and is thus a measure of sensitivity. The F1 score balances the precision p and





In order to investigate whether a given SE might be better described
from a composition of perspectives, we also proposed classification
schemes for all possible combinations of feature types. Combined models
were built from overrepresented features of each of the selected types.
Eventually, the model with a higher F1 was selected for each SE, and the infor-
mation gain upon classification wasmeasured using Shannon entropies. Here,
the probability of anticipating a SE for a given drug when using the model is
compared to the probability of anticipating the event solely based on SE
occurrence.
Similarity within System Organ Classes
For each MedDRA SOC, we collected the associated SEs and computed their
pair-wise similarity based on the previously determined enrichment signals,
i.e., two SEs are similar if they have similar overrepresentation profiles. For
independent features, we used the Jaccard coefficient of similarity. For
features organized in a DAG, we used the set-set Lin’s semantic similarity
(Pesquita et al., 2009), where the proportion of drugs annotated to each of
the overrepresented features was used to derive the information content
required by Lin’s measure. Feature-feature similarities were based on the in-
formation content of the most informative common ancestor and ultimately
used to compute the similarity between sets of features.
The similarity of SEs within a SOC was then regarded as the average of the
pair-wise SE similarities, and we estimated the significance of this measure-
ment by bootstrapping 104 samples of SE sets.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
Tables S1–S4, and Figures S1–S4 and can be found with this article online
at http://dx.doi.org/10.1016/j.chembiol.2013.03.017.
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